Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database by unknown
ENVIRONMENT AND AUTOIMMUNITY
Quadrivalent human papillomavirus vaccine
and autoimmune adverse events: a case–control
assessment of the vaccine adverse event reporting
system (VAERS) database
David A. Geier1 • Mark R. Geier1
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Gardasil is a quadrivalent human papillomavirus (HPV4) vaccine that was approved for use by the US Food and
Drug Administration in June 2006. HPV4 vaccine is routinely recommended for administration to women in the USA who
are 11–12 years old by the Advisory Committee on Immunization Practices. Previous studies suggest HPV4 vaccine
administration was associated with autoimmune diseases. As a consequence, an epidemiological assessment of the vaccine
adverse event reporting system database was undertaken for adverse event reports associated with vaccines administered
from 2006 to 2014 to 6–39 year-old recipients with a listed US residence and a specified female gender. Cases with the
serious autoimmune adverse event (SAAE) outcomes of gastroenteritis (odds ratio (OR) 4.627, 95 % confidence interval
(CI) 1.892–12.389), rheumatoid arthritis (OR 5.629, 95 % CI 2.809–12.039), thrombocytopenia (OR 2.178, 95 % CI
1.222–3.885), systemic lupus erythematosus (OR 7.626, 95 % CI 3.385–19.366), vasculitis (OR 3.420, 95 % CI
1.211–10.408), alopecia (OR 8.894, 95 % CI 6.255–12.914), CNS demyelinating conditions (OR 1.585, 95 % CI
1.129–2.213), ovarian damage (OR 14.961, 95 % CI 6.728–39.199), or irritable bowel syndrome (OR 10.021, 95 % CI
3.725–33.749) were significantly more likely than controls to have received HPV4 vaccine (median onset of initial
symptoms ranged from 3 to 37 days post-HPV4 vaccination). Cases with the outcome of Guillain–Barre syndrome (OR
0.839, 95 % CI 0.601–1.145) were no more likely than controls to have received HPV4 vaccine. In addition, cases with the
known HPV4-related outcome of syncope were significantly more likely than controls to have received HPV4 vaccine (OR
5.342, 95 % CI 4.942–5.777). Cases with the general health outcomes of infection (OR 0.765, 95 % CI 0.428–1.312),
conjunctivitis (OR 1.010, 95 % CI 0.480–2.016), diarrhea (OR 0.927, 95 % CI 0.809–1.059), or pneumonia (OR 0.785,
95 % CI 0.481–1.246) were no more likely than controls to have received HPV4 vaccine. Confirmatory epidemiological
studies in other databases should be undertaken and long-term clinical consequences of HPV-linked SAAEs should be
examined.
Keywords Adverse reaction  Gardasil  RA  Vaccination  SLE
Introduction
Genetic, immunological, hormonal, and environmental
factors are considered to be important triggers for
autoimmune diseases [1]. The ability of vaccination to
induce autoimmune illness has been debated in the litera-
ture for decades and is often surrounded by controversy [2].
It was postulated that vaccination may induce autoimmu-
nity using similar mechanisms as occurring in infection-
induced autoimmunity [1].
Gardasil (Merck & Co, Inc, Whitehouse Station, NJ,
USA) is a quadrivalent human papillomavirus (HPV4)
vaccine prepared from the purified virus-like particles
(VLPs) of the major capsid (L1) protein of HPV Types 6,
11, 16, and 18 [3]. There are approximately 20 lg of HPV
6 L1 protein, 40 lg of HPV 11 L1 protein, 40 lg of HPV
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16 L1 protein, and 20 lg of HPV 18 L1 protein in each
0.5 mL HPV4 vaccine dose. There are also approximately
225 lg of aluminum, 9.56 mg of sodium chloride, 0.78 mg
of L-histidine, 50 lg of polysorbate 80, 35 lg of sodium
borate,\7 lg yeast protein, and water for injection in each
0.5 mL dose of HPV4 vaccine. A preservative or antibiotics
are not present in HPV4 vaccine. HPV4 vaccines are to be
administered over 6 months to women between the ages of
9 and 26 years of age based upon its approval by the US
Food and Drug Administration (FDA) in June 2006, and the
HPV4 vaccine is routinely recommended for administration
to women who are 11–12 years old by the Advisory Com-
mittee on Immunization Practices (ACIP) [4].
As described in a recent review [5], the routine admin-
istration of HPV4 was associated with several cases of
onset or exacerbations of autoimmune diseases following
immunization in the literature and pharmacovigilance
databases, triggering concerns about its safety. In light of
the potential for HPV4 vaccine to be associated with
autoimmunity, a comprehensive case–control epidemio-
logical study of the vaccine adverse event reporting system
(VAERS) database to evaluate the risk for reported serious
autoimmune adverse events (SAAEs) following HPV4
vaccination was undertaken. The purpose of the present
study was to attempt to confirm and extend previous
findings of a significant relationship between HPV4 vac-
cination and SAAEs.
Materials and methods
The VAERS is an epidemiological database that has been
maintained jointly by the US Centers for Disease Control
and Prevention (CDC) and FDA since 1990 as a surveil-
lance tool to evaluate vaccine safety. Specific adverse
events following vaccination are required to be reported to
this database as mandated by law, but other adverse events
that occur following vaccine administration are passively
reported to VAERS. The VAERS Working Group of the
CDC has previously acknowledged that less than 5 % of
the total adverse events reported to VAERS are reported by
parents. Specific serious adverse events and deaths reported
to VAERS are followed-up by the CDC/FDA. The VAERS
Working Group of the CDC and the FDA has repeatedly
analyzed and published epidemiologic studies based upon
VAERS [6, 7].
The VAERS Working Group notes that VAERS is
simple to use, flexible by design, and the data are available
in a timely fashion, but it also warns that the potential
limitations may include systematic error due to underre-
porting, erroneous reporting, frequent multiple exposures,
multiple outcomes, and lack of precise denominators. In
addition, when evaluating data from VAERS, it is
important to note that, for any reported event, no cause and
effect relationship has been established. VAERS is inter-
ested in all potential associations between vaccines and
adverse events. Therefore, VAERS collects information on
any adverse event following vaccination reported by an
individual associating the adverse event with vaccination,
be it coincidental or truly caused by a vaccine [6, 7].
Determining the population at risk
An analysis of the VAERS updated through November 2015
was undertaken using the CDC Wonder online computer
interface (http://wonder.cdc.gov/vaers.html) and MedAlerts
online computer interface (http://www.medalerts.org/
vaersdb/index.php). These portals provide a direct method
for independent investigators to rapidly analyze up-to-date
data in VAERS. Adverse event reports associated with
vaccines administered from January 2006 through December
2014 to recipients between 6 and 39 years old with a listed
residence in the USA and a specified female gender was used
to identify cases and controls in the present study. Overall, a
total of 48,852 adverse event reports in females were
examined in the present study, and these adverse event
reports were reported to VAERS following administration of
HPV4 or any other vaccine(s).
Determining cases
The SAAE cases were selected from the 48,852 total
adverse event reports in females examined in the present
study and were defined with outcomes specified as gas-
troenteritis (VAERS code: 10017888), rheumatoid arthritis
(VAERS code: 10039073), Guillain–Barre syndrome
(VAERS code: 10018767), thrombocytopenia (VAERS
codes: 10043554 [thrombocytopenia] or 10043561
[thrombocytopenic purpura]), systemic lupus erythemato-
sus (VAERS code: 10042945), vasculitis (VAERS code:
10047115), alopecia (VAERS codes: 10001760 [alopecia]
or 10001761 [alopecia areata] or 10001766 [alopecia
totalis]), Central Nervous System (CNS) demyelinating
conditions (VAERS codes: demyelination of the CNS
[10012305] or multiple sclerosis [10028245] or transverse
myelitis [10028527] or optic neuritis [10030942]), ovarian
damage (VAERS codes: 10033119 [ovarian abscess] or
10033122 [ovarian atrophy] or 10033132 [ovarian cyst] or
10033136 [ovarian cyst rupture] or 10033137 [ovarian
cystectomy] or 10033157 [ovarian enlargement] or
10033165 [ovarian failure] or 10033270 [ovarian necrosis]
or 10036049 [polycystic ovaries]), and irritable bowel
syndrome (10023003). In addition, general health outcome
cases were selected from the 48,852 total adverse event
reports in females examined in the present study and were
defined with outcomes specified as infection (VAERS
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code: 10021789), conjunctivitis (VAERS code: 10010741),
diarrhea (VAERS code: 10012735), and pneumonia
(VAERS code: 10035664). Table 1 summarizes the total
number of cases for each type of outcome examined in
VAERS. Finally, in order to test the consistency of VAERS
and our epidemiological methods used in VAERS with
other epidemiological studies of HPV4 vaccine safety,
cases with the known HPV4-related outcome of syncope
[8, 9] (VAERS code: 10042772) were selected from the
from the 48,852 total adverse event reports in females
examined in the present study
Determining controls
The controls were selected from the 48,852 total adverse
event reports in females examined in the present study. The
controls were selected for each type of case outcome
examined by including only those adverse event reports
that did not include the specific type of case outcome under
study. Table 1 summarizes the total number of controls for
each type of case outcome examined in VAERS.
Determining exposure
Exposure was determined in the present study based upon
HPV4 vaccine administration (VAERS codes: 1098). It
was presumed adverse event reports that included HPV4
vaccine were exposed and adverse event reports that did
not include HPV4 vaccine were unexposed.
Statistical analyses
The Fisher’s exact test contained in the StatsDirect (version
2.8.0) statistical software package was utilized for statis-
tical analyses, and a two-sided p value\0.05 was consid-
ered to be statistically significant. Odds ratios (ORs),
p values, and 95 % confidence intervals (CIs) were calcu-
lated. The null hypothesis was that there would be no
difference in exposure to HPV4 vaccine among cases and
controls.
Results
Table 2 examines among cases with SAAEs and controls,
the frequency of exposure to HPV4 vaccine administration
in the VAERS database. It was observed that cases with the
outcomes of gastroenteritis (OR 4.627, 95 % CI
1.892–12.389, p\ 0.0005), rheumatoid arthritis (OR
5.629, 95 % CI 2.809–12.039, p\ 0.001), or thrombocy-
topenia (OR 2.178, 95 % CI 1.222–3.885, p = 0.0102),
systemic lupus erythematosus (OR 7.626, 95 % CI
3.385–19.366, p\ 0.0001), vasculitis (OR 3.420, 95 % CI
1.211–10.408, p = 0.0102), alopecia (OR 8.894, 95 % CI
6.255–12.914, p\ 0.0001), CNS demyelinating conditions
(OR 1.585, 95 % CI 1.129–2.213, p = 0.0065), ovarian
damage (OR 14.961, 95 % CI 6.728–39.199, p\ 0.0001),
or irritable bowel syndrome (OR 10.021, 95 % CI
3.725–33.749, p\ 0.0001) were significantly more likely
Table 1 A summary of various types of cases and controls examined
in the present study
Outcome examined (VAERS code) Number
Serious autoimmune adverse events
Gastroenteritis (10017888) 25
Controls 48,827
Rheumatoid arthritis (10039073) 43
Controls 48,809
Guillain–Barre syndrome (10018767) 194
Controls 48,658








Alopecia (10001760 [alopecia] or 10001761 [alopecia
areata] or 10001766 [alopecia totalis])
202
Controls 48,650
CNS demyelinating conditions (demyelination of the CNS
[10012305] or multiple sclerosis [10028245] or




Ovarian damage (10033119 [ovarian abscess] or 10033122
[ovarian atrophy] or 10033132 [ovarian cyst] or
10033136 [ovarian cyst rupture] or 10033137 [ovarian
cystectomy] or 10033157 [ovarian enlargement] or
10033165 [ovarian failure] or 10033270 [ovarian
necrosis] or 10036049 [polycystic ovaries])
55
Controls 48,797
Irritable bowel syndrome (10023003) 28
Controls 48,824














than controls to have received HPV4 vaccine. It was
observed that cases with the outcome of Guillain–Barre
syndrome (OR 0.839, 95 % CI 0.601–1.145, p = 0.314)
were no more likely than controls to have received HPV4
vaccine.
Table 3 evaluates among cases with general health
outcomes and controls, the frequency of HPV4 vaccine
administration in the VAERS database. It was observed
that cases with the outcomes of infection (OR 0.765, 95 %
CI 0.428–1.312, p = 0.378), conjunctivitis (OR 1.010,
95 % CI 0.480–2.016, p = 0.999), diarrhea (OR 0.927,
95 % CI 0.809–1.059, p = 0.272), or pneumonia (OR
0.785, 95 % CI 0.481–1.246, p = 0.328) were no more
likely than controls to have received HPV4 vaccine.
For the known HPV4 vaccine-related outcome of syn-
cope, a total of 2871 cases were exposed and 1007 cases
were not exposed and 13,197 controls were exposed, and
32,461 controls were not exposed. As a consequence, cases
with the outcome of syncope were significantly more likely
than controls to have received HPV4 vaccine (OR 5.342,
95 % CI 4.942–5.777, p\ 0.0001).
Table 4 examines the seriousness and timing of the
SAAEs that were significantly associated with HPV4
vaccine administration. It was observed among the SAAEs
examined that thrombocytopenia (39.13 %), systemic
lupus erythematosus (28.57 %), vasculitis (27.27 %) were
associated with the highest percentages of life-threatening
outcomes. It was also observed among the SAAEs exam-
ined that rheumatoid arthritis (35.48 %), CNS demyeli-
nating conditions (34.38 %), and systemic lupus
erythematosus (25.00 %) were associated with highest
percentages of permanent disabilities. Finally, the median
onset of symptoms for the SAAEs examined revealed that
vasculitis was associated with closest median onset of
symptoms following HPV4 vaccination (3 days), and
rheumatoid arthritis was associated with the longest med-
ian onset of symptoms following HPV4 vaccination
(37 days).
For the known HPV4 vaccine-related outcome of syn-
cope, it was observed that the median onset of symptoms in
syncope adverse events (n = 2187) closely associated with
HPV4 vaccination (0 days). There were 34 (1.55 %) syn-
cope adverse events considered life threatening, and 57
(2.61 %) were associated with permanent disability.
Discussion
The present epidemiological study of the VAERS database
evaluated the potential relationship between HPV4 vaccine
administration and the risk of various types of SAAEs. It
was observed that the SAAEs of gastroenteritis, rheuma-
toid arthritis, thrombocytopenia, systemic lupus erythe-
matosus, vasculitis, alopecia, CNS demyelinating
conditions, ovarian damage, and irritable bowel syndrome
were associated with HPV4 vaccine administration,
whereas the SAAE of Guillain–Barre syndrome was not
associated with HPV4 vaccine administration. In addition,
it was observed that the general health outcomes of
infection, conjunctivitis, diarrhea, and pneumonia were not
associated with HPV4 vaccine administration. Finally, it
was observed that the previously established HPV4-related
outcome of syncope was significantly associated with
HPV4 vaccine administration. The importance of these
findings is that the present study provides additional epi-
demiological evidence to support a significant association
between HPV4 vaccine administration and specific
SAAEs.
Table 2 A summary of exposure to HPV4 vaccine exposure among




























































Italicized odds ratios and p values are statistically significant
a The Fisher’s exact test was utilized
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The results obtained in the present study are consistent
with a previous assessment of the VAERS database for the
relationship between HPV4 vaccine administration and
SAAEs [10]. The previous study of VAERS revealed a
significant link between HPV4 vaccine administration and
the outcomes of gastroenteritis, arthritis, systemic lupus
erythematosus, vasculitis, alopecia, and CNS conditions
[10]. The present assessment of the VAERS is differenti-
ated from the previous assessment of the VAERS because
the data examined in the present study included a more
updated VAERS database (the previous study examined
vaccines administered from January 2006 through
December 2012 vs. the present study examined vaccines
administered from January 2006 through December 2014)
and wider age range of reports (the previous study exam-
ined vaccines administered to recipients from 18 to
39 years old vs. the present study examined vaccines
administered recipients from 6 to 39 years old).
The results obtained in the present study are consistent
with several previous clinical studies. For example,
researchers investigated the association between HPV
vaccination and autoimmune manifestations compatible
with systemic lupus erythematosus or systemic lupus ery-
thematosus-like disease in six women who presented with
such symptoms following HPV vaccination [11]. These
investigators reported that in their cases, several common
features were observed, such as personal or familial sus-
ceptibility to autoimmunity or adverse response to a prior
dose of the vaccine, both of which may be associated with
a higher risk of postvaccination autoimmunity. Favorable
response to immunosuppressant was observed in all
patients, and there was a temporal association between
HPV vaccine and the appearance of systemic lupus ery-
thematosus-like conditions. Similarly, other investigators
observed a case series of three women that had onset or
exacerbation of lupus following HPV immunization [12].
Table 3 A summary of exposure to HPV4 vaccine exposure among general health outcomes cases and controls
Group examined Number of cases (%) Number of controls (%) Odds ratio (95 % CI) p valuea
Infection
Exposed 19 15,365 0.765 (0.428–1.312) 0.378
Unexposed 54 33,414
Conjunctivitis
Exposed 13 15,371 1.010 (0.480–2.016) 0.999
Unexposed 28 33,440
Diarrhea
Exposed 320 15,064 0.927 (0.809–1.059) 0.272
Unexposed 750 32,718
Pneumonia
Exposed 26 0.785 0.785 (0.481–1.246) 0.328
Unexposed 72
a The Fisher’s exact test was utilized
Table 4 A summary of SAAEs associated with HPV4 vaccination
Group examined (n) Life threatening (%)a Permanent disability (%)a Median onset of symptomsb
Gastroenteritis (17) 1 (5.88) 3 (17.65) 7.5
Rheumatoid arthritis (31) 3 (9.68) 11 (35.48) 37
Thrombocytopenia (23) 9 (39.13) 3 (13.04) 18
Systemic lupus erythematosus (28) 8 (28.57) 7 (25.00) 23.5
Vasculitis (11) 3 (27.27) 2 (18.18) 3
Alopecia (162) 13 (8.02) 20 (12.35) 25
CNS demyelinating conditions (64) 7 (10.94) 22 (34.38) 23
Ovarian damage (48) 2 (4.17) 5 (10.42) 14
Irritable bowel syndrome (23) 3 (13.04) 3 (13.04) 13
a Some outcomes may have more than 1 occurrence in any single event report. If data are grouped by any of these items then the number in the
may exceed the total number of unique events and the associated percentage of total unique event reports will exceed 100 % in such cases
b Calculated based upon those reports with a specified date of onset of symptoms after vaccination
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Other researchers have suggested that an increasing num-
ber of cases of ovarian damage has been observed fol-
lowing HPV4 vaccine administration [13].
The results found in the present study are also supported
by biological plausible mechanisms of the constitute
components of HPV4 vaccine to induce SAAEs. The HPV4
vaccine contains purified VLPs of HPV Types 6, 11, 16,
and 18, which are adsorbed on preformed aluminum-con-
taining adjuvant (amorphous aluminum hydroxyphosphate
sulfate). The HPV4 vaccine is then prepared by combining
the adsorbed VLPs of each HPV type and additional
amounts of the aluminum-containing adjuvant in a sterile
liquid suspension [3].
A previous female animal model study revealed HPV4
vaccine administration via its aluminum-containing adju-
vant, and HPV antigens have the ability to trigger neu-
roinflammation and autoimmune reactions, further leading
to behavioral changes [14]. Other investigators described
animal models that showed aluminum exposure to inhibit
expression of female reproductive hormones and to induce
histologic changes in the ovaries [13].
In contrast to the results observed in the present study
and observed by other investigators, Arnheim-Dahlstrom
et al. [15] evaluated autoimmune, neurological, and venous
thromboembolic adverse events after immunization of
adolescent girls with HPV4 in Denmark and Sweden.
These investigators examined a cohort of 997,585 girls
aged 10–17, among whom 296,826 received a total of
696,420 HPV4 vaccine doses. Unlike the present study that
examined adverse event reports to the VAERS database,
Arnheim-Dahlstrom et al. examined incident hospital
diagnosed autoimmune, neurological, and venous throm-
boembolic events (53 different outcomes) up to 180 days
after each HPV4 vaccine dose, and rate ratios of the out-
comes were adjusted for age, country, calendar year, par-
ental country of birth, education, and socioeconomic status,
comparing vaccinated and unvaccinated person-time.
These investigators observed that the rate ratios for 20 of
23 autoimmune events were not significantly increased.
Exposure to HPV4 vaccine was significantly associated
with Behcet’s syndrome, Raynaud’s disease, and Type 1
diabetes, but these investigators described that each of
these three outcomes fulfilled only one of three predefined
signal strengthening criteria. In addition, these investiga-
tors observed that the rate ratios for five neurological
events were not significantly increased and there was no
association between exposure to HPV4 vaccine and venous
thromboembolism. It is interesting to note that despite the
number of individuals examined by Arnheim-Dahlstrom
et al., their study was significantly underpowered to even
examine many types of outcomes, and of those outcomes
examined, in many cases, relatively few outcomes were
observed in the HPV4 vaccinated group. This may
potentially be a consequence of the fact that the source for
detecting outcomes in the Arnheim-Dahlstrom et al. study
was from hospital records. It seems reasonable to hypoth-
esize that many of the conditions examined by Arnheim-
Dahlstrom et al. would not necessarily require hospital-
ization, and worse still, even if the condition eventually
might require hospitalization, the Arnheim-Dahlstrom et al.
study examined the diagnosis of the outcome in a hospital
within the first 181 days after vaccination. As a result, for
many of the outcomes examined by Arnheim-Dahlstrom
et al. that overlap that with the outcomes examined in the
present study, it was observed that there similar potential
trends for outcomes in both studies (i.e., odds ratio for
vasculitis in VAERS = 3.420 versus adjusted rate ratio in
Arnheim-Dahlstrom study = 1.55 or odds for systemic
lupus erythematosus in VAERS = 7.626 versus adjusted
rate ratio in Arnheim-Dahlstrom study = 1.35), but none
of the outcomes were significantly associated with HPV4
vaccination in the Arnheim-Dahlstrom et al. study.
Also in contrast to the present study findings, Chao et al.
[16] undertook an observation safety study of HPV4 in
189,629 women who receive one or more doses of HPV4
vaccine between August 2006 and March 2008 for new
diagnoses of autoimmune conditions within 180 days fol-
lowing each dose of HPV vaccine. These investigators
identified new-onset autoimmune conditions among HPV
recipients by electronic medical records, but then the
medical records were reviewed by clinicians to confirm the
diagnosis and determine the date of onset (only 31–40 % of
the cases were confirmed as new onset). It was observed
that there was no cluster of disease onset in relations to
vaccination timing, dose sequence or age was found for any
autoimmune condition. None of the incidence rate ratios
was significantly elevated except for Hashimoto’s disease,
but further investigation failed to reveal consistent evi-
dence for a safety signal for autoimmune thyroid condi-
tions. These investigators concluded that no autoimmune
safety signal was found in women vaccine with HPV4.
Once again, the Chao et al. [16] study, just like the pre-
viously discussed Arnheim-Dahlstrom et al. [15] study,
was apparently significantly underpowered to find potential
autoimmune conditions associated with HPV vaccination,
since more than half of the new-onset autoimmune cases
identified from electronic medical records were subse-
quently eliminated from the study following review by
clinicians.
Another study by Grimaldi-Bensouda et al. [17] evalu-
ated whether HPV4 vaccination was associated with newly
diagnosis autoimmune conditions. In Grimaldi-Bensouda
et al. study a total of 211 female cases aged 14–26 years
old from across France and diagnosed with autoimmune
diseases, and 875 controls were recruited from general
practices and were examined. There were no significant
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increases in the risks of diagnosed thrombocytopenia,
multiple sclerosis, connective disorders, Type 1 diabetes,
Guillain–Barre syndrome or thyroiditis. The investigators
concluded that none of the autoimmune disorders studied
had an increased risk following HPV4 vaccination within
the time periods studied, but the authors acknowledged that
their study was limited by statistical power. Yet again, the
Grimaldi-Bensouda et al. study, just like the previously
discussed Chao et al. [16] and Amheim-Dahlstrom et al.
[15] studies, was significantly underpowered to find
potential autoimmune conditions associated with HPV
vaccination, since there were fewer than 10 cases exposed
for each of the autoimmune disorders examined (throm-
bocytopenia = 6, connective tissue disorders = 6, central
demyelination = 4, Guillain–Barre syndrome = 0, and
Type 1 diabetes = 9).
Strengths/limitations
It was previously described that an ‘‘unmasking’’ phe-
nomenon is a concern with many epidemiological studies
evaluating vaccine safety among adolescents and young
adults because they may undergo a workup and subsequent
diagnosis of preexisting conditions following a visit at
which a vaccination is administered [18]. The epidemio-
logical method employed to examine VAERS database in
this study ensured that the exposures to the various types of
vaccines studied occurred prior to the outcomes described
in the adverse event reports, since those reporting the
adverse outcomes associated the outcomes with the vac-
cines listed in the adverse event reports. Further, since
everyone examined in the present study had to have
received a vaccine (i.e., vaccine receipt is a necessary
requirement for reporting to VAERS), it is believed that
this ‘‘unmasking’’ phenomenon should have applied
equally to everyone examined.
Another strength was that the VAERS data were col-
lected independently of the study design used in the present
study. Among those reporting the adverse event reports
examined, it was highly unlikely that any of them could
have envisioned methods of analysis used to evaluate the
potential relationship between HPV4 vaccine and the
adverse events examined.
An additional strength of the present study was the
specificity of the types of the SAAEs associated with HPV4
vaccine. Namely, despite the fact that a number of different
types of potential SAAEs were examined for the relation-
ship with HPV4 vaccine administration, it was observed
that the types of SAAE outcomes significantly associated
with HPV4 vaccination are biologically plausibly associ-
ated with HPV4 vaccine administration from previous
clinical and animal model studies. Further, previous epi-
demiological assessment of the VAERS database revealed
that laboratory findings consistent with the SAAE out-
comes found to be significantly linked with HPV4 vaccine
administration in the present study, such as positive
rheumatoid factor, positive antinuclear antibodies, and
positive antiphospholipid antibodies were significantly
associated with HPV4 vaccine administration [10]. Finally,
among the SAAEs associated with HPV4 vaccine admin-
istration, it was observed, consistent with the biological
plausible onset window for SAAEs following vaccination,
that the median onset of symptoms ranged between 3 and
37 days post-immunization.
However, the results observed in this study may have a
number of potential limitations. It is possible the results
observed may have occurred from unknown biases or
cofounders present in the datasets examined. This seems
unlikely because the general health outcomes of infection,
conjunctivitis, diarrhea, and pneumonia were examined,
and all were observed to be exposed to HPV4 vaccine at a
similar frequency as controls. In addition, the known
HPV4-related outcome of syncope was examined in the
present study, and it was observed that the risk of syncope
(OR 5.342, 95 % CI 4.942–5.777) was very similar to that
reported by previous investigators examining California
Kaiser Permanente medical records (OR 6.0, 95 % CI
3.9–9.2) [9].
An additional potential limitation of this study is that
VAERS may have shortcomings, such as underreporting,
difficulty in determining causal relationship, and a lack
of precise denominators. Nevertheless, as previously
described by investigators from the CDC, almost all of
these types of shortcomings would apply equally to
VAERS reports after vaccines administered to similar
populations [19]. The case–control method employed in
the present study ensured that all of the adverse event
reports examined in VAERS were administered to sim-
ilar populations (i.e., age and gender), and as a result,
examining the relative exposure to HPV4 vaccine among
the cases and controls identified from the adverse event
reports examined in VAERS should provide accurate
relative qualitative and quantitative relationships between
differing vaccine exposures and adverse outcomes.
Additionally, investigators previously employed similar
case–control study designs to the one used in the present
study to successfully evaluate the potential relationship
between vaccine administration and various SAAEs
[10, 20].
Another potential limitation of the present study is that
the results observed may be the result of statistical chance.
However, such a possibility would be unlikely given the
limited number of statistical tests performed, the highly
significant results observed (most p values observed were
\0.01), and the consistency in the direction and magnitude
of the results observed.
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Still, other potential limitations of this study include the
possibilities that some of the individuals in VAERS may
have had more subtle adverse events that were not brought
to the attention of their healthcare providers, healthcare
providers may have misdiagnosed some individuals, or
some vaccine exposures may not have been appropriately
classified. These limitations, while possibly present in the
data examined in the current study, should not have sig-
nificantly impacted the results observed because it is
unclear how differential application would have occurred
based upon different exposures among cases and controls.
Moreover, misclassification occurring in the data examined
would tend to bias any results observed toward the null
hypothesis, since such effects would result in individuals
being placed in the wrong exposure and/or outcome cate-
gories examined, and result in decreased statistical power
to determine true potential exposure-outcome relationships.
In addition, another potential limitation of this study is
that other sources of exposure among cases and controls
were not evaluated. It is possible that the findings may be
the result of other components of the vaccines studied
which, in isolation or synergistically, interacted with the
HPV4 vaccine examined.
Finally, the current study suffers from the potential
limitation that analyses were not conducted to further
explore the cumulative dosing effects from HPV4 vaccine
administration or to compare HPV vaccine administration
with unvaccinated populations. In future studies, it would
be worthwhile to further explore these precise-timing and
cumulative-doses phenomena. In addition, it would be
valuable to evaluate other adverse events, as well as other
covariates such as race, prior medical history, etc., that may
further affect the magnitude of the adverse effects found.
Conclusion
In conclusion, this epidemiological study provides addi-
tional evidence to support a significant relationship
between HPV4 vaccine administration and SAAEs. The
results in this study are consistent with a number of pre-
vious case series of SAAEs observed following HPV4
vaccine administration, previous epidemiological studies
linking HPV4 vaccine with SAAEs and other outcomes,
and are consistent with the known biological plausibility of
HPV4 vaccine administration to induce SAAEs in some
vaccine recipients. In light of the findings of the present
study, we recommend that additional studies be conducted
to further evaluate the potential epidemiological relation-
ship between HPV4 vaccine-associated SAAEs in other
databases and populations and to further evaluate the long-
term clinical consequences of HPV-linked SAAEs.
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